Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPMY Astellas Pharma	$9.30 +0.8%	$9.63	$8.37 ▼ $13.14	N/A	0.24	127,258 shs	260,945 shs
DSNKY Daiichi Sankyo	$22.90 +1.1%	$24.71	$20.92 ▼ $42.48	$42.92B	N/A	192,213 shs	308,511 shs
REGN Regeneron Pharmaceuticals	$511.92 +0.4%	$557.15	$476.49 ▼ $1,211.20	$55.03B	0.31	890,573 shs	1.08 million shs
ZTS Zoetis	$157.51 +0.2%	$159.72	$139.70 ▼ $200.33	$69.97B	0.94	2.55 million shs	2.39 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPMY Astellas Pharma	0.00%	-4.15%	-4.75%	-7.70%	-3.05%
DSNKY Daiichi Sankyo	0.00%	-7.89%	-13.98%	-9.87%	-33.12%
REGN Regeneron Pharmaceuticals	0.00%	-3.69%	-13.36%	-22.89%	-51.60%
ZTS Zoetis	0.00%	-4.27%	-3.47%	-3.65%	-8.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPMY Astellas Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	4.8252 of 5 stars	4.4	4.0	1.7	2.3	2.2	1.7	1.9
ZTS Zoetis	4.6235 of 5 stars	3.5	3.0	4.2	0.4	3.5	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPMY Astellas Pharma	0.00	N/A	N/A	N/A
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
REGN Regeneron Pharmaceuticals	2.85	Moderate Buy	$836.48	63.40% Upside
ZTS Zoetis	3.00	Buy	$212.13	34.67% Upside

Current Analyst Ratings Breakdown

Latest ALPMY, ZTS, REGN, and DSNKY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$633.00 ➝ $560.00
6/2/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$700.00 ➝ $650.00
6/2/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$800.00 ➝ $600.00
6/2/2025	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$958.00 ➝ $755.00
5/30/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/30/2025	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$662.00
5/30/2025	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$700.00 ➝ $580.00
5/27/2025	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Sector Perform	$943.00 ➝ $662.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPMY Astellas Pharma	$12.56B	N/A	$1.81 per share	5.13	$5.52 per share	N/A
DSNKY Daiichi Sankyo	$12.39B	3.50	$1.27 per share	18.05	$5.61 per share	4.08
REGN Regeneron Pharmaceuticals	$14.20B	3.89	$45.91 per share	11.15	$268.50 per share	1.91
ZTS Zoetis	$9.26B	7.58	$7.09 per share	22.23	$10.57 per share	14.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPMY Astellas Pharma	$334.93M	$0.17	54.71	13.68	N/A	2.65%	16.55%	7.35%	7/29/2025 (Estimated)
DSNKY Daiichi Sankyo	$1.95B	$1.03	22.23	21.01	1.16	15.65%	17.92%	8.61%	7/29/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.03	13.46	1.87	31.94%	15.27%	11.93%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	28.28	23.33	2.61	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest ALPMY, ZTS, REGN, and DSNKY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion
4/25/2025	Q4 2025	ALPMY Astellas Pharma	$0.1474	$0.27	+$0.1226	$0.27	$3.02 billion	$3.22 billion
4/25/2025	Q4 2025	DSNKY Daiichi Sankyo	N/A	$0.30	N/A	$0.30	N/A	$3.40 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPMY Astellas Pharma	$0.35	3.76%	N/A	205.88%	N/A
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.69%	N/A	8.96%	N/A
ZTS Zoetis	$2.00	1.27%	N/A	35.91%	14 Years

Latest ALPMY, ZTS, REGN, and DSNKY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPMY Astellas Pharma	0.37	1.13	0.85
DSNKY Daiichi Sankyo	0.06	2.53	1.85
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPMY Astellas Pharma	N/A
DSNKY Daiichi Sankyo	N/A
REGN Regeneron Pharmaceuticals	83.31%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
ALPMY Astellas Pharma	N/A
DSNKY Daiichi Sankyo	N/A
REGN Regeneron Pharmaceuticals	7.02%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPMY Astellas Pharma	14,754	N/A	N/A	Not Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable
ZTS Zoetis	13,800	445.21 million	444.50 million	Optionable

ALPMY, ZTS, REGN, and DSNKY Headlines

Recent News About These Companies

Oppenheimer Asset Management Inc. Acquires 43,325 Shares of Zoetis Inc. (NYSE:ZTS)

June 23 at 7:19 AM | marketbeat.com

2 S&P 500 Stocks on Our Watchlist and 1 to Think Twice About

June 23 at 6:59 AM | finance.yahoo.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Sawgrass Asset Management LLC

June 23 at 6:15 AM | marketbeat.com

Kentucky Retirement Systems Insurance Trust Fund Lowers Stock Position in Zoetis Inc. (NYSE:ZTS)

June 23 at 5:05 AM | marketbeat.com

Cullinan Associates Inc. Sells 2,400 Shares of Zoetis Inc. (NYSE:ZTS)

June 23 at 4:38 AM | marketbeat.com

Intact Investment Management Inc. Boosts Stake in Zoetis Inc. (NYSE:ZTS)

June 23 at 4:37 AM | marketbeat.com

76,510 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Vantage Investment Partners LLC

June 22 at 6:09 AM | marketbeat.com

Harvey Investment Co. LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 22 at 5:59 AM | marketbeat.com

Wealth Enhancement Advisory Services LLC Sells 157,309 Shares of Zoetis Inc. (NYSE:ZTS)

June 22 at 3:21 AM | marketbeat.com

Fishman Jay A Ltd. MI Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 21 at 7:31 AM | marketbeat.com

Union Savings Bank Lowers Position in Zoetis Inc. (NYSE:ZTS)

June 21 at 7:31 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Holdings Raised by Nilsine Partners LLC

June 21 at 7:09 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Appleton Partners Inc. MA

June 21 at 6:16 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Cabot Wealth Management Inc.

June 21 at 5:59 AM | marketbeat.com

Dupont Capital Management Corp Acquires 27,864 Shares of Zoetis Inc. (NYSE:ZTS)

June 21 at 5:32 AM | marketbeat.com

Covea Finance Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

June 21 at 5:22 AM | marketbeat.com

Envestnet Portfolio Solutions Inc. Has $6.77 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 21 at 4:23 AM | marketbeat.com

Boston Trust Walden Corp Buys 7,542 Shares of Zoetis Inc. (NYSE:ZTS)

June 21 at 4:23 AM | marketbeat.com

Unusually Active Put Options Signal Long Straddle Opportunity After Zoetis Downgrade

June 20 at 8:52 PM | finance.yahoo.com

SGIOY or ZTS: Which Is the Better Value Stock Right Now?

June 20 at 12:41 PM | zacks.com

S&P Futures Slip as Israel-Iran Conflict Remains in Focus

June 20 at 8:47 AM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPMY, ZTS, REGN, and DSNKY Company Descriptions

Astellas Pharma OTCMKTS:ALPMY

$9.30 +0.07 (+0.76%)

As of 03:59 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Daiichi Sankyo OTCMKTS:DSNKY

$22.90 +0.24 (+1.07%)

As of 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Regeneron Pharmaceuticals NASDAQ:REGN

$511.92 +2.20 (+0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$515.99 +4.07 (+0.80%)

As of 07:56 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Zoetis NYSE:ZTS

$157.51 +0.34 (+0.22%)

Closing price 03:59 PM Eastern

Extended Trading

$157.67 +0.16 (+0.10%)

As of 07:44 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time